Home » Newsletters » BioWorld Science

BioWorld Science

April 16, 2004

View Archived Issues

Synergistic effects of MB40 in prostate cancer models

Two new human monoclonal anticollagen antibodies from CancerVax inhibit tumor growth in vivo

Neuroprotective effects of FR-255595, a PARP-1 inhibitor, reported by Fujisawa

ImClone presents an anti-VEGFR-1 antibody effective against human breast cancers in vivo

IMC-11F8, an anti-EGFR monoclonal antibody, effective antitumor agent in vivo

KID3, a glycotope-specific IgG monoclonal antibody, inhibits colon and gastric tumor growth

Small potent BACE1 inhibitors against beta-amyloid plaque formation

Three series of DPP-IV inhibitors prepared and tested at Boehringer Ingelheim

Merckle scientists present two series of p38 MAP kinase inhibitors

New inhibitors of 5-HT and/or NE reuptake and their use in pain and other disorders

Lilly claims NE reuptake inhibitors with potential in ADHD therapy

New CRF1 modulators in early development at Neurogen

Celltech patent covers novel IMPDH inhibitors and their use

HCT-1026 reduces beta-amyloid deposition in mouse model of Alzheimer's

Genome Therapeutics changes name to Oscient Pharmaceuticals

Approval for treatment protocol for Ceplene plus IL-2 in malignant melanoma

Fuzeon to be made available through U.S. pharmacies

Accentia enters licensing agreements for chronic rhinosinusitis

Norak Biosciences and Scynexis enter chemistry collaboration

Oxxon Therapeutics, new name for Oxxon Pharmaccines

SBIR grant supports Kosan's development of next-generation Hsp90 inhibitors

Subcutaneous icatibant produces positive results in bioavailability study

Myriad Genetics licenses rights to new colon cancer gene MYH

Health Canada approves extension study of Tectin

Zadaxin in combination with lamivudine investigated for hepatitis B

Mixed initial results for Fampridine-SR in MS and spinal cord injury

FDA approval for ChiRhoClin's human secretin

Torcetrapib increases HDL cholesterol levels and may be beneficial for CHD patients

Alicaforsen reported effective for chronic pouchitis following anastomosis for ulcerative colitis

Clinical trials confirm the benefits of cinacalcet in secondary HPT

Promising compounds against drug-resistant tuberculosis